Compare Procter & Gamble Co (PG) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Procter & Gamble Co vs Health Care Select Sector SPDR Fund — how do they compare? Procter & Gamble Co trades at $149.49 (market cap $344.87B), while Health Care Select Sector SPDR Fund trades at $159.56. The key difference: Procter & Gamble Co pays a 2.94% dividend while Health Care Select Sector SPDR Fund pays none, and Health Care Select Sector SPDR Fund is trading nearer its 52-week high, Procter & Gamble Co nearer its low. Which is the better fit depends on your goals.
| PG | XLV | |
|---|---|---|
Market Cap | $344.87B | — |
Volume | 6,423,436 | — |
Sector | Consumer Staples | — |
52-Week High | $167.18 | $164.48 |
52-Week Low | $138.10 | $129.01 |
Enterprise Value | $370.34B | — |
Dividend Yield | 2.94% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Procter & Gamble (PG) trades at $149.15, showing minimal daily movement. The stock exhibits neutral technical signals with support near $147 and resistance at $150. Fundamentally, PG maintains stable revenue near $84.3 billion and strong net income margins above 19%, supported by consistent earnings beats. Recent news highlights its dividend reliability amid market volatility, with a 69-year track record of increases. Analyst consensus is bullish with a $160.50 price target, though valuation multiples trade at premiums to peers.
PG offers steady growth with dividend safety but faces near-term headwinds from premium valuations and modest revenue expansion. Upside depends on execution of supply chain efficiencies and sustained consumer demand. Risks include competitive pressures and economic sensitivity. Institutional ownership trends show mixed positioning, reflecting cautious optimism.
XLV trades at $159.25, down 1.14% with neutral technical signals overall. The healthcare ETF shows mixed momentum with bullish moving averages but neutral oscillators. Recent news highlights XLV's defensive characteristics amid market volatility, with State Street upgrading healthcare to positive for Q3 2026. The fund's diversified approach offers stability compared to more volatile biotech-focused alternatives.
XLV presents a defensive opportunity with lower costs and steady performance, though upside may be limited in the current cycle. Key risks include patent cliff concerns and sector rotation away from defensive plays if market sentiment improves. The ETF's broad healthcare exposure provides cushion against individual stock volatility while benefiting from pipeline innovations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
